Literature DB >> 12525559

Rational approaches to human cancer immunotherapy.

Ian D Davis1, Michael Jefford, Phillip Parente, Jonathan Cebon.   

Abstract

Over most of the 20th century, immunotherapy for cancer was based on empiricism. Interesting phenomena were observed in the areas of cancer, infectious diseases, or transplantation. Inferences were made and extrapolated into new approaches for the treatment of cancer. If tumors regressed, the treatment approaches could be refined further. However, until the appropriate tools and reagents were available, investigators were unable to understand the biology underlying these observations. In the early 1990s, the first human tumor T cell antigens were defined and dendritic cells were discovered to play a pivotal role in antigen presentation. The current era of cancer immunotherapy is one of translational research based on known biology and rationally designed interventions and has led to a rapid expansion of the field. The beginning of the 21st century brings the possibility of a new era of effective cancer immunotherapy, combining rational, immunological treatments with conventional therapies to improve the outcome for patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525559     DOI: 10.1189/jlb.0502261

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  23 in total

Review 1.  Targeting the dendritic cell: the key to immunotherapy in cancer?

Authors:  A Faith; C M Hawrylowicz
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 2.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

3.  Direct stimulation of T cells by membrane vesicles from antigen-presenting cells.

Authors:  Marek Kovar; Onur Boyman; Xuefei Shen; Inkyu Hwang; Rachel Kohler; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-19       Impact factor: 11.205

4.  Evaluation of cancer-preventive activity and structure-activity relationships of 3-demethylubiquinone Q2, isolated from the ascidian Aplidium glabrum, and its synthetic analogs.

Authors:  Sergey N Fedorov; Oleg S Radchenko; Larisa K Shubina; Nadezhda N Balaneva; Ann M Bode; Valentin A Stonik; Zigang Dong
Journal:  Pharm Res       Date:  2006-12-05       Impact factor: 4.200

5.  A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.

Authors:  Adva Levy; Jacob Pitcovski; Shoshana Frankenburg; Orit Elias; Yael Altuvia; Hanna Margalit; Tamar Peretz; Jacob Golenser; Michal Lotem
Journal:  Cell Immunol       Date:  2008-02-13       Impact factor: 4.868

Review 6.  Cancer immunotherapy via dendritic cells.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

7.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

8.  A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells.

Authors:  Young Seob Kim; Hyun Jin Park; Jung Hwa Park; Eun Ji Hong; Gun-Young Jang; In Duk Jung; Hee Dong Han; Seung-Hyun Lee; Manh-Cuong Vo; Je-Jung Lee; Andrew Yang; Emily Farmer; T-C Wu; Tae Heung Kang; Yeong-Min Park
Journal:  Oncoimmunology       Date:  2018-08-15       Impact factor: 8.110

9.  Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.

Authors:  Qiyuan Chen; Heather Jackson; Phillip Parente; Tina Luke; Mark Rizkalla; Tsin Yee Tai; He-Cheng Zhu; Nicole A Mifsud; Nektaria Dimopoulos; Kelly-Anne Masterman; Wendie Hopkins; Heather Goldie; Eugene Maraskovsky; Simon Green; Lena Miloradovic; James McCluskey; Lloyd J Old; Ian D Davis; Jonathan Cebon; Weisan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

Review 10.  Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.

Authors:  Jorge Schettini; Pinku Mukherjee
Journal:  Clin Dev Immunol       Date:  2009-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.